OakChart

Minerva Neurosciences Inc

NERVHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

2.56+0.07 (2.81%)
2026-11-12 01:56 CET
Market cap
124.09 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-296.76 USD m
Free cash flow, TTM
-31.40 USD m
EPS diluted, TTM
-28.69
P/E
-
Compare

Price

NERV against its 20, 50 and 200-day averages
2050200beat
2.004.006.001.9M3.9MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26NERVclose 2.5620-day 2.3850-day 3.10200-day 4.832.5652w low

70.9% under the 52-week high of 8.80 on 16 Mar 2026. 52-week low 1.96 on 30 Oct 2026. Last 15 sessions, 40.8% high to low

Volume 0.48× normal · the line is the 50-bar volume average

Profile

NERV
52-week range, 9% of the way up
1.968.80

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson's disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.

IndexRUT
Employees7
IPOJul 01, 2014
Beta0.01
ATR, 14d0.26
Rel volume0.48
Short float4.82%
Insider own21.08%
Inst own73.14%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap127.58M
Enterprise Value122.28M
Income-296.76M
Sales0.00M
Book/sh-1.96
Cash/sh1.55
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees7
IPOJul 01, 2014

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B-
P/C1.66
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio33.02
Current Ratio33.02
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)-28.69
EPS next Y-0.67
EPS next Q-0.17
EPS this Y-4.94%
EPS next Y66.39%
EPS next 5Y36.24%
EPS past 3/5Y-79.32% -
Sales past 3/5Y- -
EPS Y/Y TTM-1306.84%
Sales Y/Y TTM-
EPS Q/Q48.91%
Sales Q/Q-
EarningsNov 06 BMO
EPS/Sales Surpr.-13.98% -

Ownership

Insider Own21.08%
Insider Trans0.00%
Inst Own73.14%
Inst Trans2.91%
ROA-460.33%
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA207.62%
SMA50-17.44%
SMA200-46.99%
Trades-

Technical

Shs Outstand49.84M
Shs Float39.33M
Short Float4.82%
Short Ratio9.60
Short Interest1.90M
52W High8.80 -70.91%
52W Low1.96 30.61%
Volatility14.28% 11.61%
ATR (14)0.26
RSI (14)47.46
Beta0.01
Rel Volume0.48
Avg Volume197.55K
Volume95,705

Performance

Perf Week-0.39%
Perf Month1.79%
Perf Quarter-34.69%
Perf Half Y-53.87%
Perf YTD-36.32%
Perf Year-35.52%
Perf 3Y-37.56%
Perf 5Y-76.30%
Perf 10Y-97.63%
Recom1.67
Target Price10.33
Prev Close2.49
Price2.56
Change %2.81%

Analyst ratings

latest 10 of 11
DateActionAnalystRating changeTargetImplied
Aug 14, 2026UpgradeJJefferiesHold → Buy$10+290.6%
Apr 15, 2026InitiatedCCitizensMkt Outperform$14+446.9%
Jun 08, 2020ReiteratedHH.C. WainwrightBuy$20 → $10+290.6%
May 14, 2020InitiatedBBTIG ResearchBuy$23+798.4%
Oct 02, 2019ReiteratedCChardan Capital MarketsBuy$17+564.1%
Sep 25, 2019InitiatedCChardan Capital MarketsBuy$17+564.1%
Sep 18, 2019InitiatedWWilliam BlairOutperform
May 31, 2019InitiatedHH.C. WainwrightBuy
Sep 01, 2017InitiatedCCitigroupBuy$11+329.7%
Mar 06, 2017ResumedJJefferiesBuy$17+564.1%

Peers

Mkt cap
TickerCompanyMkt cap
MPLTMapLight Therapeutics Inc415.70M
LBRXLB Pharmaceuticals Inc1.45B
NMRANeumora Therapeutics Inc88.87M
ANROAlto Neuroscience Inc1.22B
ACADAcadia Pharmaceuticals Inc3.17B
VNDAVanda Pharmaceuticals Inc250.95M
AVXLAnavex Life Sciences Corp98.26M
AXSMAxsome Therapeutics Inc7.85B
ALKSAlkermes plc8.05B
SUPNSupernus Inc6.12B

Insider trading

6 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Federated Hermes Kaufmann Fund10% OwnerMar 31 '26Proposed Sale8.008,79870,384Mar 31 05:00 PM
Federated Hermes Kaufmann Smal10% OwnerMar 31 '26Proposed Sale8.0019,838158,704Mar 31 04:57 PM
Federated Hermes Kaufmann Fund10% OwnerMar 31 '26Proposed Sale8.0031,808254,464Mar 31 04:57 PM
Federated Hermes Kaufmann Fund10% OwnerMar 10 '26Proposed Sale8.0012,45699,648Mar 10 05:20 PM
Federated Hermes Kaufmann Smal10% OwnerMar 10 '26Proposed Sale8.00264,6152,116,920Mar 10 05:15 PM
Federated Hermes Kaufmann Fund10% OwnerMar 10 '26Proposed Sale8.00424,2783,394,224Mar 10 05:15 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IWCiShares Micro-Cap ETFAUM: 1.22B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B
QQQSInvesco NASDAQ Future Gen 200 ETFAUM: 20.53M
RSSLGlobal X Russell 2000 ETFAUM: 1.43B

News

latest 14 of 198
  • Minerva Neurosciences: Q3 Earnings Snapshot (Associated Press) +5.22%
  • Minerva Neurosciences Provides Third Quarter 2026 Financial Results and Business Updates (GlobeNewswire)
  • Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in London (GlobeNewswire)
  • Minerva Neurosciences to Host In-Person KOL Event to Discuss Roluperidone for Negative Symptoms of Schizophrenia (GlobeNewswire)
  • Minerva Neurosciences to Participate in Two Upcoming Investor Conferences (GlobeNewswire) -5.65%
  • Minerva Neurosciences: Q2 Earnings Snapshot (Associated Press)
  • Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates (GlobeNewswire)
  • Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs (GlobeNewswire)
  • Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference (GlobeNewswire) -9.02% -8.02%
  • Minerva Neurosciences: Q1 Earnings Snapshot (Associated Press)
  • Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates (GlobeNewswire)
  • Minerva Announces Leadership Transition (GlobeNewswire) -5.71%
  • Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia (GlobeNewswire) -7.05%
  • Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026 (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-06-0.190-0.167-0.1900.000.003
2026Q22026-08-07-0.140-0.193-0.1380.000.003
2026Q12026-05-05-2.860-0.127-2.8570.000.003
2025Q42026-03-11-0.640-0.302-25.5140.000.002
2025Q32025-11-05-0.360--0.3630.00--
2025Q22025-08-14-0.430--0.4310.00--
2025Q12025-05-13-0.500-1.070-0.4960.000.001
2024Q42025-02-25-0.560-1.050-0.5640.000.001
2024Q32024-11-052.970-1.0102.9740.000.001
2024Q22024-08-06-1.090-0.970-1.0880.000.001
2024Q12024-05-01-1.130-1.200-1.1320.000.001
2023Q42024-02-22-1.190-0.880-1.1920.000.001
2023Q32023-11-07-1.030-0.770-1.0330.000.001
2023Q22023-08-01-1.120-0.717-1.1240.000.002
2023Q12023-05-15-1.310-1.290-1.3050.000.002
2022Q42023-03-08-1.260-1.010-1.2600.000.004

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-14.800-11.722-14.8010.000.00
2020FY0.4000.2390.37941.1841.19
2021FY-9.360-6.813-9.3450.000.33
2022FY-6.010-3.900-6.0130.000.00
2023FY-4.610-4.260-4.6120.000.00
2024FY0.190-0.3000.1900.000.00
2025FY-1.890-1.592-34.6700.000.00
2026FY--1.983--0.00
2027FY--0.667--0.00
2028FY--0.490--19.12
2029FY-0.000--80.86
2030FY-0.775--221.38

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-062000.000.000.00
2026Q4S2026-08-072000.000.000.00
2026Q4S2026-05-052000.000.000.00
2026Q4S2026-04-142000.000.000.00
2026Q4S2026-03-111000.000.000.00
2026Q4S2025-11-111000.000.000.00
2026Q4S2025-11-101000.000.000.00
2026Q4S2025-11-091000.000.000.00
2026Q4S2025-11-081000.000.000.00
2026Q4S2025-11-071000.000.000.00
2026Q4S2025-11-061000.000.000.00
2026Q4R2026-11-06200-0.18-0.24-0.12
2026Q4R2026-10-21100-0.24-0.24-0.24
2026Q4R2026-08-07110-0.24-0.24-0.24

Estimate history

EPS, annual-6.64-10.347-14.8010.379-9.345-6.013-4.6120.19-34.669-28.694
Period201720182019202020212022202320242025TTM
EPS, quarterly2.974-0.564-0.496-0.431-0.363-25.514-2.857-0.138-0.185
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual00041.176000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual4.8444.8674.8865.345.345.346.9936.99343.27449.835
Period201720182019202020212022202320242025MRQ
Shares, quarterly6.9936.9936.9936.9936.99343.27443.84247.22749.835
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.0041.180.000.00
Cost of Goods Sold Incl. D&A0.000.010.020.030.010.100.180.160.02
Gross Profit-0.00-0.01-0.02-0.03-0.01-0.1041.00-0.16-0.02
Selling, General and Administrative Excl. Other41.7315.1021.8323.0925.2245.2639.1556.7051.71
Research and Development19.775.7611.9012.7114.6532.0422.0439.1234.89
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-41.73-15.10-21.85-23.12-25.23-45.371.85-56.87-51.73
Interest Expense--4.568.287.410.000.000.000.11
Unusual Expense251.42279.210.000.000.000.000.0019.00-
Net Income Before Taxes-290.86-293.421.44-30.01-32.11-51.711.94-74.44-50.17
Income Taxes0.000.000.000.000.00-1.800.00-2.250.00
Consolidated Net Income-290.86-293.421.44-30.01-32.11-49.911.94-72.18-50.17
Net Income From Continuing Operations-290.86-293.421.44-30.01-32.11-49.911.94-72.18-50.17
Net Income-296.76-293.421.44-30.01-32.11-49.911.94-72.18-50.17
EPS (Recurring)-3.43-11.580.19-4.61-6.01-9.350.38-12.07-10.35
EPS (Basic, Before Extraordinaries)-26.07-34.670.19-4.61-6.01-9.350.38-14.80-10.35
EPS (Diluted)-28.69-34.670.19-4.61-6.01-9.350.38-14.80-10.35
EBITDA-41.73-15.10-21.83-23.09-25.22-45.262.02-56.70-51.71
Non-Operating Income (Expense)2.290.8927.851.400.53-6.340.091.431.67
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense14.651.331.331.974.115.229.706.708.18
Price To Earnings Ratio------40.36--
Price To Sales Ratio------2.33--
Gross Margin------99.57--
Operating Margin------4.49--
Net Margin------4.71--
Shares Outstanding49.8443.276.996.995.345.345.344.894.87
Market Capitalization124.09124.0915.5443.018.4934.2299.97277.89262.44

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.00
Gross Profit0.000.000.00-0.00-0.00-0.00-0.00-0.00
Selling, General and Administrative Excl. Other9.4310.6416.674.982.843.373.904.52
Research and Development5.167.195.252.170.931.301.361.98
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-9.43-10.64-16.67-4.98-2.84-3.37-3.90-4.52
Unusual Expense-109.60-27.55109.36279.210.000.000.000.00
Net Income Before Taxes100.7517.47-125.40-283.67-2.74-3.26-3.75-4.27
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income100.7517.47-125.40-283.67-2.74-3.26-3.75-4.27
Net Income From Continuing Operations100.7517.47-125.40-283.67-2.74-3.26-3.75-4.27
Net Income95.6616.65-125.40-283.67-2.74-3.26-3.75-4.27
EPS (Recurring)-1.20-0.38-1.11-7.93-0.36-0.43-0.50-0.56
EPS (Basic, Before Extraordinaries)1.940.36-2.86-25.51-0.36-0.43-0.50-0.56
EPS (Diluted)-0.19-0.14-2.86-25.51-0.36-0.43-0.50-0.56
EBITDA-9.43-10.64-16.67-4.98-2.84-3.37-3.90-4.52
Non-Operating Income (Expense)0.580.560.630.530.100.120.150.25
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.212.278.710.460.270.300.300.25
Price To Earnings Ratio----1.422.088.94-
Shares Outstanding49.8447.2343.8443.276.996.996.996.99
Market Capitalization124.09258.57260.7328.1114.7212.0311.8915.54

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments82.4021.4641.0136.1960.8625.4645.9588.10128.24
Short Term Receivables0.000.000.003.120.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.700.810.990.851.351.981.181.921.30
Total Current Assets83.1022.2742.0040.1662.2027.4447.1490.02129.54
Net Property, Plant & Equipment0.000.010.010.020.050.100.280.030.05
Total Investments and Advances0.000.000.000.000.000.000.000.005.02
Intangible Assets14.8714.8714.8914.9114.8730.0730.0749.0749.07
Deferred Tax Assets0.000.000.000.000.002.352.355.295.29
Other Assets0.000.000.000.000.000.010.010.010.01
Total Assets97.9737.1456.9055.0977.1259.9879.85144.43188.98
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.110.170.003.96
Accounts Payable0.641.611.810.971.851.002.321.801.44
Other Current Liabilities1.651.231.540.410.972.054.141.811.44
Total Current Liabilities2.292.843.341.382.823.166.633.616.84
Long Term Debt64.9660.0082.0273.730.000.000.110.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.000.000.000.000.004.154.169.359.34
Other Liabilities171.460.000.000.0066.330.0041.1841.2041.21
Total Liabilities238.7262.8485.3675.1169.157.3152.0754.1657.39
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity-140.75-25.69-28.46-20.027.9852.6627.7890.26131.60
Total Shareholders Equity-140.75-25.69-28.46-20.027.9852.6627.7890.26131.60
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity-140.75-25.69-28.46-20.027.9852.6627.7890.26131.60
Total Liabilities & Stockholders Equity97.9737.1456.9055.0977.1259.9879.85144.43188.98
Book Value Per Share-3.25-3.67-4.07-3.751.499.865.6918.5527.17
Tangible Book Value Per Share-3.60-5.80-6.20-6.54-1.294.23-0.478.4617.04
Full-Time Employees7899911131312
Price to Book Ratio-1.27-0.72-2.15-0.604.291.9010.002.911.80
Return on Assets-434.343.06-53.59-48.57-72.802.78-64.37-30.10-19.58
Return on Equity-----164.604.83-122.30-45.23-26.54
Return on Invested Capital-4.19-56.02-59.78-625.733.69-258.81-55.58-23.95
Quick Ratio36.287.8512.5729.1522.078.687.1124.9418.94
Current Ratio36.287.8512.5729.1522.078.687.1124.9418.94

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-290.86-293.421.44-30.01-32.11-49.911.94-72.18-50.17
Depreciation0.000.010.020.030.010.100.180.160.02
Other Funds (Non Cash)265.13280.54-20.6910.2511.5226.759.6227.418.10
Funds from Operations-25.72-12.88-19.23-19.72-20.58-24.8611.73-46.87-42.05
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-5.68-0.63-0.324.94-4.060.26-45.563.430.11
Cash from Operating Activities-31.40-13.51-19.55-14.78-24.65-24.60-33.82-43.43-41.94
Capital Expenditures0.000.000.000.00-0.020.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-55.860.000.000.000.000.0024.5314.0869.49
Purchase of Investments-78.360.000.000.000.000.00-3.87-61.09-40.66
Sale Or Maturity of Investments22.500.000.000.000.000.0028.4075.18110.15
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-55.860.000.000.00-0.020.0024.5314.0869.49
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock95.3474.450.0019.600.000.0013.240.520.66
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock95.3474.450.0019.600.000.0013.240.520.66
Proceedsfrom Stock Options-6.36-5.550.00-0.400.000.0012.090.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.00-4.00
Change in Long Term Debt0.000.000.000.000.000.000.000.00-4.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00-4.00
Net Financing Active Other Cash Flow-0.150.000.000.00-5E-0660.000.000.000.00
Other Financing Activities Uses-0.150.000.000.00-5E-060.000.000.000.00
Cash from Financing Activities95.1974.450.0019.60-5E-0660.0013.240.52-3.34
Net Change in Cash7.9360.94-19.554.82-24.6635.403.94-28.8224.20
Free Cash Flow-31.40-13.51-19.55-14.78-24.66-24.60-33.82-43.43-41.94
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.00-1.800.00-2.250.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments77.0475.3778.1682.4012.3915.35
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets6.364.370.940.700.630.20
Total Current Assets83.4179.7379.1183.1013.0215.55
Net Property, Plant & Equipment0.000.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets14.8714.8714.8714.8714.8714.87
Deferred Tax Assets---0.00--
Other Assets0.000.490.050.000.200.00
Total Assets98.2895.0994.0397.9728.0930.42
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable0.651.452.120.640.940.90
Other Current Liabilities1.872.512.361.651.731.63
Total Current Liabilities2.533.964.482.292.672.53
Long Term Debt71.7471.7464.9664.9660.0060.00
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---0.00--
Other Liabilities121.53232.69278.60171.460.000.00
Total Liabilities195.80308.39348.04238.7262.6762.53
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-97.52-213.30-254.01-140.75-34.58-32.11
Total Shareholders Equity-97.52-213.30-254.01-140.75-34.58-32.11
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-97.52-213.30-254.01-140.75-34.58-32.11
Total Liabilities & Stockholders Equity98.2895.0994.0397.9728.0930.42
Book Value Per Share-1.96-4.52-5.79-3.25-4.94-4.59
Tangible Book Value Per Share-2.26-4.83-6.13-3.60-7.07-6.72
Full-Time Employees---7--
Price to Book Ratio-1.27-0.96-1.85-0.81-0.46-0.41
Return on Assets-460.33-628.40-654.56-434.34-39.5729.28
Return on Invested Capital-----10.79-11.68
Quick Ratio33.0220.1417.6536.284.876.15
Current Ratio33.0220.1417.6536.284.876.15

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income100.7517.47-125.40-283.67-2.74-3.26
Depreciation0.000.000.000.000.000.00
Other Funds (Non Cash)-106.79-25.68117.93279.670.270.30
Funds from Operations-6.05-8.21-7.47-4.00-2.47-2.96
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-2.10-5.132.04-0.49-0.450.92
Cash from Operating Activities-8.15-13.34-5.43-4.48-2.92-2.04
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-5.73-4.83-45.290.000.000.00
Purchase of Investments-23.23-9.83-45.290.000.000.00
Sale Or Maturity of Investments17.505.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-5.73-4.83-45.290.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock9.4410.271.1774.450.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock9.4410.271.1774.450.000.00
Proceedsfrom Stock Options-0.56-0.23-0.03-5.550.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.00-0.10-0.090.05-0.050.00
Other Financing Activities Uses0.00-0.10-0.090.05-0.050.00
Cash from Financing Activities9.4410.171.0874.50-0.050.00
Net Change in Cash-4.44-8.01-49.6470.02-2.96-2.04
Free Cash Flow-8.15-13.34-5.43-4.48-2.92-2.04

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-305.03%1.9M37.7M185.71K
2026-10-156.39%2.4M37.7M182.61K
2026-09-306.46%2.4M37.7M193.33K
2026-09-156.43%2.4M37.7M257.87K
2026-08-315.64%2.1M37.4M253.41K
2026-08-144.69%1.8M37.4M225.29K
2026-07-316.60%2.4M37.1M219.29K
2026-07-156.53%2.4M37.1M222.17K
2026-06-305.14%1.9M37.1M226.99K
2026-06-153.02%1.1M37.1M229.42K
2026-05-292.69%1.0M36.5M258.83K
2026-05-153.25%1.2M36.5M248.11K
2026-04-303.45%1.3M38.5M254.08K
2026-04-153.24%1.2M35.7M238.69K
2026-03-312.86%1.0M35.7M213.53K
2026-03-131.57%0.6M35.7M114.44K
2026-02-271.23%0.4M35.7M76.12K
2026-02-131.21%0.4M35.7M75.60K
2026-01-301.07%0.4M37.8M69.39K
2026-01-150.85%0.3M37.8M2.82M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.003.200.200.0004550.000.0000.0000.000
call5.000.004.600.000.0000.000.000.0000.0000.000
call7.500.000.100.100.0004.000.000.980-0.0300.000
put2.500.003.200.400.00027.000.000.0000.0000.000
put5.000.005.000.000.0000.000.000.0000.0000.000
put7.502.507.400.0029.5320.000.00-0.861-0.0230.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-068-KCurrent report2026-11-06SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-10-27SCHEDULE 13GSEC
2026-08-203Initial statement of beneficial ownership of securities2026-08-10SEC
2026-08-203Initial statement of beneficial ownership of securities2026-08-10SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-128-KCurrent report2026-08-10SEC
2026-08-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-078-KCurrent report2026-08-07SEC
2026-08-034Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-07-08SCHEDULE 13G/ASEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-048-KCurrent report2026-06-03SEC
2026-05-278-KCurrent report2026-05-27SEC
2026-05-27424B5SEC
2026-05-15SCHEDULE 13GSEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-058-KCurrent report2026-05-05SEC
2026-04-23ARSAnnual report to security holders. 2025-12-31SEC
2026-04-23DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-23DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-03SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
FEDERATED HERMES, INC.10.02%
Jupiter Topco LLC9.41%
Vivo Capital, LLC9.28%
BALYASNY ASSET MANAGEMENT L.P.9.14%
Logos Global Management LP7.06%
FARALLON CAPITAL MANAGEMENT, L.L.C.5.08%
BlackRock, Inc.4.81%
Ally Bridge Group4.67%
Foresite Capital Management VI LLC4.26%
VANGUARD CAPITAL MANAGEMENT LLC4.06%

Funds

Fund% owned
Federated Hermes Kaufmann Fund5.16%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.83%
iShares Russell 2000 ETF1.40%
VANGUARD EXTENDED MARKET INDEX FUND1.10%
Fidelity Small Cap Index Fund0.79%
Fidelity Extended Market Index Fund0.48%
iShares Russell 2000 Growth ETF0.47%
VANGUARD RUSSELL 2000 INDEX FUND0.41%
Federated Hermes Kaufmann Small Cap Fund0.35%
iShares Micro-Cap ETF0.24%

OakChart. NERV. Cached 15 minutes.